Literature DB >> 26821759

Leading causes of certifiable visual loss in England and Wales during the year ending 31 March 2013.

A Quartilho1, P Simkiss2, A Zekite1, W Xing1, R Wormald1,3, C Bunce1,3.   

Abstract

PURPOSE: The last article on causes of sight impairment (SI) in England and Wales was for April 2007-March 2008. This report updates these figures for April 2012-March 2013.
METHODS: In England and Wales, registration for SI is initiated by completion of a certificate of vision impairment (CVI). The main cause of visual impairment was ascertained for certificates completed April 2012-March 2013. A proportional comparison against April 2007-March 2008 was made.
RESULTS: We received 24 009 CVIs of which 10 410 were for severe sight impairment (SSI) and 13 129 were for SI. These numbers were slightly higher than those observed in April 2007-March 2008 (9823 SSI; 12 607 SI). The ratio SI:SSI has remained static with 55% of all certifications being SI. The proportion of certificates without a single main cause has fallen slightly (16.6 to 14%). The proportion of certificates with a main cause of degeneration of the macula and posterior pole (mostly age-related macular degeneration (AMD)) decreased from 58.6 to 50% SSI and from 57.2 to 52.5% SI. Glaucoma remains the second most common cause (11% SSI; 7.6% SI) but hereditary retinal disorders overtook diabetes as third leading cause of SSI.
CONCLUSION: AMD is still by far the leading cause of certifications for sight impairment in England and Wales (both SI and SSI). Proportionate changes have been observed since 2008, but it is important to note that a proportionate increase in one condition will impact on others.

Entities:  

Mesh:

Year:  2016        PMID: 26821759      PMCID: PMC5108547          DOI: 10.1038/eye.2015.288

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  6 in total

1.  Department of Health and Social Security. Reports on Public Health and Medical Subjects. No. 128. The incidence and causes of blindness in England and Wales 1963-68. With an appendix on services available for incipient blindness.

Authors:  A Sorsby
Journal:  Rep Public Health Med Subj (Lond)       Date:  1972

2.  Causes of blind and partial sight certifications in England and Wales: April 2007-March 2008.

Authors:  C Bunce; W Xing; R Wormald
Journal:  Eye (Lond)       Date:  2010-09-17       Impact factor: 3.775

3.  Causes of blind certifications in England and Wales: April 1999-March 2000.

Authors:  C Bunce; R Wormald
Journal:  Eye (Lond)       Date:  2007-03-02       Impact factor: 3.775

4.  Geographical variation in certification rates of blindness and sight impairment in England, 2008-2009.

Authors:  Aeesha N J Malik; Catey Bunce; Richard Wormald; Mehrunisha Suleman; Irene Stratton; J A Muir Gray
Journal:  BMJ Open       Date:  2012-11-19       Impact factor: 2.692

5.  Certification for vision impairment: researching perceptions, processes and practicalities in health and social care professionals and patients.

Authors:  T Boyce; Shaun Leamon; J Slade; P Simkiss; S Rughani; Faruque Ghanchi
Journal:  BMJ Open       Date:  2014-04-08       Impact factor: 2.692

6.  Leading causes of certification for blindness and partial sight in England & Wales.

Authors:  Catey Bunce; Richard Wormald
Journal:  BMC Public Health       Date:  2006-03-08       Impact factor: 3.295

  6 in total
  35 in total

1.  Voice-controlled virtual assistants for the older people with visual impairment.

Authors:  D K-H Ho
Journal:  Eye (Lond)       Date:  2017-08-04       Impact factor: 3.775

2.  Uveitis certifications.

Authors:  A Quartilho; P Simkiss; A Zekite; W Xing; R Wormald; C Bunce
Journal:  Eye (Lond)       Date:  2016-06-17       Impact factor: 3.775

3.  Visual loss in uveitis.

Authors:  N P Jones
Journal:  Eye (Lond)       Date:  2016-06-17       Impact factor: 3.775

4.  Activation of Rod Input in a Model of Retinal Degeneration Reverses Retinal Remodeling and Induces Formation of Functional Synapses and Recovery of Visual Signaling in the Adult Retina.

Authors:  Tian Wang; Johan Pahlberg; Jon Cafaro; Rikard Frederiksen; A J Cooper; Alapakkam P Sampath; Greg D Field; Jeannie Chen
Journal:  J Neurosci       Date:  2019-07-08       Impact factor: 6.167

5.  A Deep Learning Approach for Automated Detection of Geographic Atrophy from Color Fundus Photographs.

Authors:  Tiarnan D Keenan; Shazia Dharssi; Yifan Peng; Qingyu Chen; Elvira Agrón; Wai T Wong; Zhiyong Lu; Emily Y Chew
Journal:  Ophthalmology       Date:  2019-06-11       Impact factor: 12.079

6.  The Association of Aspirin Use with Age-Related Macular Degeneration Progression in the Age-Related Eye Disease Studies: Age-Related Eye Disease Study 2 Report No. 20.

Authors:  Tiarnan D Keenan; Henry E Wiley; Elvira Agrón; Mary E Aronow; William G Christen; Traci E Clemons; Emily Y Chew
Journal:  Ophthalmology       Date:  2019-06-26       Impact factor: 12.079

7.  DeepSeeNet: A Deep Learning Model for Automated Classification of Patient-based Age-related Macular Degeneration Severity from Color Fundus Photographs.

Authors:  Yifan Peng; Shazia Dharssi; Qingyu Chen; Tiarnan D Keenan; Elvira Agrón; Wai T Wong; Emily Y Chew; Zhiyong Lu
Journal:  Ophthalmology       Date:  2018-11-22       Impact factor: 12.079

8.  Age-related Macular Degeneration: Nutrition, Genes and Deep Learning-The LXXVI Edward Jackson Memorial Lecture.

Authors:  Emily Y Chew
Journal:  Am J Ophthalmol       Date:  2020-06-20       Impact factor: 5.258

9.  Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report Number 19.

Authors:  Tiarnan D Keenan; Susan Vitale; Elvira Agrón; Amitha Domalpally; Andrew N Antoszyk; Michael J Elman; Traci E Clemons; Emily Y Chew
Journal:  Ophthalmol Retina       Date:  2019-06-11

Review 10.  Are we ready for genetic testing for primary open-angle glaucoma?

Authors:  Anthony P Khawaja; Ananth C Viswanathan
Journal:  Eye (Lond)       Date:  2018-01-30       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.